<h1>Indian Competition Commission Approves Pharma Merger with Conditions; Requires Divestitures in Seven Markets to Ensure Fair Competition.</h1> The Competition Commission of India approved the merger between two pharmaceutical companies, subject to modifications. The approval requires the companies to divest products in seven relevant markets for formulations to address potential adverse effects on competition. The merger cannot proceed until these divestitures are completed. The decision followed an investigation into market shares, competition, and potential vertical foreclosure in the active pharmaceutical ingredients market. The Commission concluded that the merger's competitive concerns could be mitigated through these specified modifications under the Competition Act, 2002.